House dust mite SLIT-tablet is well tolerated in pediatric patients with controlled asthma.

IF 2.3 4区医学 Q3 ALLERGY

Asian Pacific journal of allergy and immunology Pub Date : 2024-12-01 DOI:10.12932/AP-051220-1009

Hisashi Tanida, Takayasu Nomura, Yuto Kondo, Yasutaka Hirabayashi, Jun Wakatsuki, Shinji Saitoh

{"title":"House dust mite SLIT-tablet is well tolerated in pediatric patients with controlled asthma.","authors":"Hisashi Tanida, Takayasu Nomura, Yuto Kondo, Yasutaka Hirabayashi, Jun Wakatsuki, Shinji Saitoh","doi":"10.12932/AP-051220-1009","DOIUrl":null,"url":null,"abstract":"Background: : Despite the reported clinical effectiveness of house dust mite (HDM) sublingual immunotherapy (SLIT) in pediatric patients, the risk of treatment remains unclear in pediatric patients with allergic asthma.Objective: To show a risk of adverse drug reactions (ADRs) in pediatric patient with allergic asthma during the initiation period of HDM SLIT.Methods: We retrospectively analyzed the clinical data of pediatric patients aged ≤ 15 years who initiated allergen immunotherapy (AIT) with the SQ HDM SLIT-tablet for allergic rhinitis between February 2017 and September 2019. Asthma severity at baseline and ADRs during the first 4 weeks of the treatment were determined for each subject.Results: In our study population (n = 217; median age, 8.4 years), 99 patients (45.6%) were classified as having asthma. One hundred and one patients (46.5%) in the whole cohort experienced ADRs during the first 4 weeks of therapy, but a major gap in the frequency of ADRs was not observed between an asthma group and a non-asthma group.Conclusions: The SQ HDM SLIT-tablet was well tolerated in pediatric patients with controlled HDM-driven allergic asthma. HDM-SLIT is an option to treat their allergic rhinitis without excessive concern for its ADRs.","PeriodicalId":8552,"journal":{"name":"Asian Pacific journal of allergy and immunology","volume":" ","pages":"368-371"},"PeriodicalIF":2.3000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asian Pacific journal of allergy and immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.12932/AP-051220-1009","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ALLERGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: : Despite the reported clinical effectiveness of house dust mite (HDM) sublingual immunotherapy (SLIT) in pediatric patients, the risk of treatment remains unclear in pediatric patients with allergic asthma.

Objective: To show a risk of adverse drug reactions (ADRs) in pediatric patient with allergic asthma during the initiation period of HDM SLIT.

Methods: We retrospectively analyzed the clinical data of pediatric patients aged ≤ 15 years who initiated allergen immunotherapy (AIT) with the SQ HDM SLIT-tablet for allergic rhinitis between February 2017 and September 2019. Asthma severity at baseline and ADRs during the first 4 weeks of the treatment were determined for each subject.

Results: In our study population (n = 217; median age, 8.4 years), 99 patients (45.6%) were classified as having asthma. One hundred and one patients (46.5%) in the whole cohort experienced ADRs during the first 4 weeks of therapy, but a major gap in the frequency of ADRs was not observed between an asthma group and a non-asthma group.

Conclusions: The SQ HDM SLIT-tablet was well tolerated in pediatric patients with controlled HDM-driven allergic asthma. HDM-SLIT is an option to treat their allergic rhinitis without excessive concern for its ADRs.

查看原文本刊更多论文

受控哮喘的儿童患者对屋尘螨 SLIT 片剂的耐受性良好。

背景：：尽管有报道称屋尘螨（HDM）舌下免疫疗法（SLIT）对儿科患者临床有效，但过敏性哮喘儿科患者的治疗风险仍不明确：显示过敏性哮喘儿科患者在开始使用屋尘螨舌下免疫疗法期间发生药物不良反应（ADRs）的风险：我们回顾性分析了2017年2月至2019年9月期间使用SQ HDM SLIT片剂开始过敏原免疫疗法（AIT）治疗过敏性鼻炎的15岁以下儿科患者的临床数据。对每位受试者基线时的哮喘严重程度和治疗前4周的不良反应进行了测定：在我们的研究人群（n = 217；中位年龄，8.4 岁）中，99 名患者（45.6%）被归类为哮喘患者。在整个组群中，有 111 名患者（46.5%）在治疗的前 4 周内出现了不良反应，但在哮喘组和非哮喘组之间没有观察到不良反应发生频率上的重大差距：结论：SQ HDM SLIT 片剂在受 HDM 控制的过敏性哮喘儿童患者中耐受性良好。HDM-SLIT是治疗过敏性鼻炎的一种选择，无需过分担心其不良反应。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Asian Pacific journal of allergy and immunology 医学-过敏

CiteScore

12.80

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： The Asian Pacific Journal of Allergy and Immunology (APJAI) is an online open access journal with the recent impact factor (2018) 1.747 APJAI published 4 times per annum (March, June, September, December). Four issues constitute one volume. APJAI publishes original research articles of basic science, clinical science and reviews on various aspects of allergy and immunology. This journal is an official journal of and published by the Allergy, Asthma and Immunology Association, Thailand. The scopes include mechanism, pathogenesis, host-pathogen interaction, host-environment interaction, allergic diseases, immune-mediated diseases, epidemiology, diagnosis, treatment and prevention, immunotherapy, and vaccine. All papers are published in English and are refereed to international standards.